These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 15974556)

  • 1. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
    Sullivan PW; Nair KV; Patel BV
    Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis.
    Lee J; Cummins G; Okamoto L
    Am J Manag Care; 2001 May; 7(4 Suppl):S103-12. PubMed ID: 11392821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines.
    Sullivan PW; Nichol MB
    Value Health; 2004; 7(4):402-12. PubMed ID: 15449632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-the-counter drug use by medicare beneficiaries in nursing homes: implications for practice and policy.
    Simoni-Wastila L; Stuart BC; Shaffer T
    J Am Geriatr Soc; 2006 Oct; 54(10):1543-9. PubMed ID: 17038072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
    Liao E; Leahy M; Cummins G
    Am J Manag Care; 2001 Oct; 7(15 Suppl):S459-68. PubMed ID: 11680261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
    Trygstad TK; Hansen RA; Wegner SE
    J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis.
    Sullivan PW; Follin SL; Nichol MB
    Med Care; 2003 Dec; 41(12):1382-95. PubMed ID: 14668671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?
    Shiffman S; Sweeney CT
    Health Policy; 2008 Apr; 86(1):17-26. PubMed ID: 17935827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of benefit design change across 5 disease states.
    Brixner DI; Joish VN; Odera GM; Avey SG; Hanson DM; Cannon HE
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):370-6. PubMed ID: 17567238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coupon programs curb antihistamine utilization.
    Berberabe T
    Manag Care; 2003 Aug; 12(8):28-9. PubMed ID: 12966848
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and utilization impacts of oral antihistamines in the California Medi-Cal program.
    Hay JW; Leahy M
    Value Health; 2005; 8(4):506-16. PubMed ID: 16091028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of new and continuing prescription drug use on cost: a longitudinal analysis of chronic and seasonal utilization.
    Fairman KA
    Clin Ther; 2000 May; 22(5):641-52. PubMed ID: 10868561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population.
    Balkrishnan R; Byerly WG; Camacho FT; Shrestha A; Anderson RT
    Am J Manag Care; 2001 Nov; 7(11):1093-100. PubMed ID: 11725812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting.
    Nash DB; Sullivan SD; Mackowiak J
    Am J Manag Care; 2000 Jan; 6(1 Suppl):S3-15; quiz S19-20. PubMed ID: 11009751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is reliance on self-medication and pharmacy care adequate for rhinitis patients?
    Williams A; Scadding G
    Int J Clin Pract; 2009 Jan; 63(1):98-104. PubMed ID: 19125997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly.
    Liu SZ; Romeis JC
    Health Policy; 2004 Jun; 68(3):277-87. PubMed ID: 15113639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
    Spencer HM
    Am Univ Law Rev; 2002 Jun; 51(5):999-1050. PubMed ID: 12197546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.